Skip to content

Spirulina in covid 19

Effect of Spirulina as a nutritional supplement and drug in Covid-19 patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20101201005287N4
Enrollment
100
Registered
2022-06-06
Start date
2021-12-10
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19,Virus identified. COVID19 , Virus identified

Interventions

Intervention 1: Intervention group: For 14 days ,patients received the Spirulina capsule(1g) prepared in Tabriz school of Pharmacy , while visiting the Imam Reza hospital from a researcher , consuming

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: confirmation of Covid19 by PCR test satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Having an underlying disease peregnancy stop taking the drug

Design outcomes

Primary

MeasureTime frame
Interleukin-6 blood levels of patients before and after taking the drug. Timepoint: Before starting the drug and 14 days after taking the drug. Method of measurement: Blood sample analysisfor IL-6 by ELIZA in the labratory.

Secondary

MeasureTime frame
Serum TNF-a levels in patients plasma. Timepoint: Before starting the drug and 14 days after starting the drug. Method of measurement: Blood sample analysis for TNF-a by ELIZA in the laboratory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkbar Sharifi

Tabriz University of Medical Sciences

asharifi@tbzmrd.ac.ir+98 41 3371 5449

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026